18F-FDG PET/CT双时相显像对胰腺良恶性病变鉴别的诊断价值

doi:10.6040/j.issn.1671-7554.0.2015.1011

摘要/Abstract

摘要： 目的评价PET/CT双时相显像对胰腺良恶性病变鉴别诊断的应用价值。方法对81例胰腺恶性病变和41例胰腺良性病变行¹⁸F-FDG PET/CT常规显像,其中46例胰腺恶性病变和22例胰腺良性病变行PET/CT延迟显像。寻求早期最大标准摄取值(SUV_早期)和滞留指数(RI)的最佳诊断界值。结果胰腺恶性病变组SUV_早期(5.46±3.51)明显高于良性病变组SUV_早期(1.89±1.28)(P<0.05),胰腺恶性病变组SUV_延迟(5.87±3.79)高于良性病变组SUV_延迟(2.64±1.94)(P<0.05)。其中68例行PET/CT双时相显像的胰腺病变患者中,胰腺良性病变组SUV_早期(2.33±1.25)和SUV_延迟(2.64±1.94)差异无统计学意义(P>0.05);胰腺恶性病变组SUV_早期(4.52±2.98)和SUV_延迟(5.87±3.79)差异有统计学意义(P<0.05)。根据ROC曲线,以SUV_早期=2.75为本研究的最佳诊断界值,灵敏度、特异度和准确度分别为82.72%、80.49%和81.97%;以RI%=12.04%为界值,灵敏度、特异度和准确度分别为82.61%、72.72%和79.41%;以SUV_早期=2.75和RI%=12.04%为联合诊断标准,灵敏度、特异度和准确度分别为93.48%、59.10%和82.35%。结论 ¹⁸F-FDG PET/CT双时相显像对胰腺良恶性病变有良好的鉴别诊断价值。

关键词: 胰腺癌, PET/CT, ¹⁸F-FDG, 双时相, 标准摄取值

Abstract: Objective To evaluate the diagnostic value of dual-phase PET/CT in the differential diagnosis of benign and malignant pancreatic lesions. Methods The ¹⁸F-FDG PET/CT conventional imaging was performed on 81 cases of malignant pancreatic lesions and 41 cases of benign pancreatic lesions. Of them, 46 of the malignant cases and 22 of the benign cases received delayed imaging. The best cut-off point value of maximum standardized uptake value for early phase(SUV_early)and retention index(RI)were explored. Results Among the 122 cases undergoing ¹⁸F-FDG PET / CT examination, SUV_early of malignant cases(5.46±3.51)was significantly higher than that of benign cases(1.89±1.28)(P<0.05), while SUV_delay of malignant cases(5.87±3.79)was higher than that of benign cases(2.64±1.94)(P<0.05). Among the 68 cases undergoing the dual-phase PET/CT, there was no significant difference between SUV_early(2.33±1.25)and SUV_delay(2.64±1.94)in benign cases(P>0.05), while in malignant cases, SUV_delay(5.87±3.79)was significantly higher than SUV_early(4.52±2.98)(P<0.05). According to the ROC curve, when the best cut-off value of SUV_early was 2.75, the sensitivity, specificity and accuracy were 82.72%, 80.49% and 81.97% respectively. When RI%=12.04% was set as the boundary value, the sensitivity, specificity and accuracy were 82.61%, 72.72% and 79.41%, respectively. When SUV_early=2.75 and RI%=12.04% were jointly considered, the 山东大学学报 (医学版)54卷4期 -孙旭怡,等.¹⁸F-FDG PET/CT双时相显像对胰腺良恶性病变鉴别的诊断价值 \=-sensitivity, specificity and accuracy were 93.48%, 59.10% and 82.35%, respectively. Conclusion ¹⁸F-FDG dual-phase PET/CT has a good diagnostic value in differentiating benign pancreatic lesions from malignant ones.

Key words: Pancreatic cancer, ¹⁸F-FDG, Dual-Phase, Standardized uptake value, PET/CT

中图分类号:

R574

孙旭怡,韩建奎. ¹⁸F-FDG PET/CT双时相显像对胰腺良恶性病变鉴别的诊断价值[J]. 山东大学学报（医学版）, 2016, 54(4): 68-73.

SUN Xuyi, HAN Jiankui. Dual-Phase ¹⁸F-FDG PET/CT in the diagnosis of benign and malignant pancreatic lesions[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 68-73.

参考文献

[1] Wang XL, Yang F, Jin C, et al. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer[J]. World J Gastroenterol, 2014, 20(42): 15580-15589.
[2] Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis[J]. J Comput Assist Tomogr, 2005, 29(4): 438-445.
[3] Tang S, Huang G, Liu J, et al. Usefulness of ¹⁸F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis[J]. European Journal of Radiology, 2011, 78(1): 142-150.
[4] Lodge MA, Lucas JD, Marsden PK, et al. A PET study of ¹⁸FDG uptake in soft tissue masses[J]. Eur J Nucl Med, 1999, 26(1): 22-30.
[5] Kawada N, Uehara H, Hosoki T, et al. Usefulness of Dual-Phase ¹⁸F-FDG PET/CT for Diagnosing Small Pancreatic Tumors[J]. Pancreas, 2015, 44(4): 655-659.
[6] Nakamoto Y, Higashi T, Sakahara H, et al. Delayed(¹⁸)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas[J]. Cancer, 2000, 89(12): 2547-2554.
[7] Rijkers AP, Valkema BR, Duivenvoorden HJ, et al. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis[J]. Eur J Surg Oncol, 2014, 40(7): 794-804.
[8] Nishiyama Y, Yamamoto Y, Monden T, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour[J]. Nucl Med Commun, 2005, 26(10): 895-901.
[9] Yoshioka M, Uchinami H, Watanabe G, et al. F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors[J]. Springerplus, 2015, 4: 154.
[10] Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[¹⁸F] -fluoro-2-deoxy-D-glucose positron emission tomograpgy[J]. Gut, 1995, 36(5): 771-777.
[11] Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies[J]. Surg Oncol Clin N Am, 2010, 19(2): 235-254.
[12] Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography[J]. Gastroenterol, 2008, 43(2): 144-151.
[13] Kamisawa T, Takum K, Anjiki H, et al. FDG-PET/CT findings of autoimmune pancreatitis[J]. Hepatogastroenterology, 2010, 57(99-100): 447-450.
[14] Shigekawa M, Yamao K, Sawaki A, et a1. Is ¹⁸F-fluorodeoxyglueose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?[J]. J Hepatobiliary Pancreat Sci, 2010, 17(3): 269-274.
[15] Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases[J]. Eur J Nucl Med, 1997, 24(6): 678-682.
[16] von Forstner C, Egberts JH, Ammerpohl O, et al. Gene expression patterns and tumor uptake of ¹⁸F-FDG, ¹⁸F-FLT, and ¹⁸F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer[J]. J Nucl Med, 2008, 49(8): 1362-1370.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

¹⁸F-FDG PET/CT双时相显像对胰腺良恶性病变鉴别的诊断价值

Dual-Phase ¹⁸F-FDG PET/CT in the diagnosis of benign and malignant pancreatic lesions

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

多维度评价

本文评价

推荐阅读 0

[1]	许玉军,柳明,何祥萌,李成利. 1.0T开放型磁共振引导经皮穿刺¹²⁵I放射性粒子植入治疗晚期胰腺癌[J]. 山东大学学报（医学版）, 2017, 55(2): 21-25.
[2]	高昂, 王世江, 付正, 孙新东, 于金明, 孟雪. ¹⁸F-FDG PET/CT确定局部晚期非小细胞肺癌加量放疗靶区的可行性[J]. 山东大学学报（医学版）, 2015, 53(7): 73-77.
[3]	李红霞, 董蕾, 姜炅, 王新阳. 酪酪肽对胰腺癌Miapaca-2细胞凋亡的影响[J]. 山东大学学报（医学版）, 2015, 53(12): 7-11.
[4]	徐晖, 聂春兰. 胰腺癌伴血清甲胎蛋白升高1例临床报告[J]. 山东大学学报（医学版）, 2014, 52(S1): 120-121.
[5]	李梅影1，李际盛1，于学军1,孙丽美1，王艾君1，刘奇迹2，王秀问1. 蟾毒灵对CAPAN-2胰腺癌细胞增殖和细胞周期的影响[J]. 山东大学学报(医学版), 2013, 51(11): 37-41.
[6]	梁旭阳，程宝泉，贾俊英，王旭，任洪波. 丙酮酸乙酯对人胰腺癌细胞的抑制作用[J]. 山东大学学报(医学版), 2011, 49(5): 48-53.